Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Patients with ≥1 prior line of therapy were ...

New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed. We conducted a phase 1 clinical trial to ...

Please provide your email address to receive an email when new articles are posted on . Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs.

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety ...

Hizentra® is the first and only immune globulin (Ig) available in prefilled syringes, offering those living with Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy ...

Intravenous (IV) insulin therapy is a method of delivering insulin directly into someone’s bloodstream. Healthcare professionals may use IV insulin to treat people with high blood sugar levels. High ...